cancer immunotherapy Archives
Nanoparticles boost anti-cancer immunity
Aug. 16, 2022—An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.
Couple’s gift helps support immunotherapy research
Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.
Breast cancer cells ‘steal’ nutrients from immune cells: study
Apr. 1, 2021—Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.
A “torque” for tumor blood vessels
Aug. 20, 2020—Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies.
Potential new cancer target
Jun. 4, 2020—Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.
Patient’s cancer treatment includes new immunotherapy
Feb. 27, 2020—Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.
New prostate cancer treatment concept
Aug. 22, 2019—Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.
Encephalitis identified as rare toxicity of immunotherapy treatment
Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Discovery points to new cancer immunotherapy option
Feb. 21, 2019—An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment
Jan. 7, 2019—GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.
Breast cancer-killing RIG
Dec. 13, 2018—A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.
Immunotherapies linked to specific heart complications
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
